A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To compare the efficacy of lamivudine (3TC) and zidovudine (AZT) in combination versus the better of didanosine (ddI) monotherapy or ddI/AZT combination, in symptomatic HIV-1 infected children who received less than 56 days of prior antiretroviral therapy. To evaluate the safety and tolerance of 3TC/AZT in this patient population. To determine other measures of diseases in response to the study regimens.
Currently, none of the potential treatments for HIV-1 infection has proven to be both nontoxic and effective in long-term use. However, previous studies in both adults and children have shown that 3TC combined with AZT reduced HIV load in blood and increased white blood cells. Additionally, 3TC has demonstrated a favorable safety profile.
| Condition | Intervention | Phase |
|---|---|---|
|
HIV Infections |
Drug: Lamivudine Drug: Zidovudine Drug: Didanosine |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | A Randomized Comparative Study of Combined Zidovudine-Lamivudine (3TC) vs. the Better of ddI Monotherapy vs. Zidovudine Plus Ddl in Symptomatic HIV-1 Infected Children |
| Estimated Enrollment: | 740 |
| Primary Completion Date: | January 2001 (Final data collection date for primary outcome measure) |
Currently, none of the potential treatments for HIV-1 infection has proven to be both nontoxic and effective in long-term use. However, previous studies in both adults and children have shown that 3TC combined with AZT reduced HIV load in blood and increased white blood cells. Additionally, 3TC has demonstrated a favorable safety profile.
Patients are randomized to receive oral 3TC/AZT, ddI/AZT, or ddI alone for at least 24 months. PER AMENDMENT 4/29/96: NOTE: Randomization to ZDV+ddI arm was terminated in Spring of 1996 based upon the results of ACTG 152. Patients on that arm will continue on blinded study drug and will be followed until the end of the study.
Eligibility| Ages Eligible for Study: | 3 Months to 15 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
- IVIG.
- Prophylaxis for opportunistic infection.
- EPO.
- G-CSF or GM-CSF.
Patients must have:
- Symptomatic HIV infection.
- Less than 56 days of prior antiretroviral therapy.
- Consent of parent or guardian.
NOTE:
- Co-enrollment on ACTG 219, ACTG 220, and certain ACTG opportunistic infection protocols is permitted.
Prior Medication:
Allowed:
- Up to 56 days of prior antiretroviral therapy.
- Prior immunomodulator therapy.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Malignancy.
- Hypersensitivity to a nucleoside analog.
- Current grade 2 or higher amylase/lipase toxicity or grade 3 or 4 other toxicity.
PER AMENDMENT 4/29/96:
- Active opportunistic infection and/or serious bacterial infection at the time of entry.
Concurrent Medication:
Excluded:
- Any other anti-HIV therapy.
- Megestrol acetate ( Megace ).
- Probenecid.
- IV pentamidine.
- Human growth hormone ( hGH ).
- Systemic corticosteroids for more than 2 weeks.
Prior Medication:
Excluded:
- Investigational drug therapy within 14 days prior to study entry.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00001066
Show 91 Study Locations
| Study Chair: | McKinney RE | ||
| Study Chair: | Johnson GM |
More Information
Additional Information:
Publications:
| ClinicalTrials.gov Identifier: | NCT00001066 History of Changes |
| Other Study ID Numbers: | ACTG 300 |
| Study First Received: | November 2, 1999 |
| Last Updated: | March 1, 2011 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
|
Didanosine Drug Therapy, Combination Acquired Immunodeficiency Syndrome |
AIDS-Related Complex Zidovudine Lamivudine |
Additional relevant MeSH terms:
|
Lamivudine Zidovudine Anti-HIV Agents Anti-Infective Agents Anti-Retroviral Agents Antimetabolites Antiviral Agents |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Nucleic Acid Synthesis Inhibitors Pharmacologic Actions Reverse Transcriptase Inhibitors Therapeutic Uses |
ClinicalTrials.gov processed this record on March 03, 2015